Description
[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.0.47″][et_pb_row admin_label=”row” _builder_version=”3.21.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.0.47″][et_pb_text admin_label=”Text” _builder_version=”3.21.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]
This affinity-purified polyclonal guinea pig antiserum was specifically prepared to provide investigators with an insulin antiserum that demonstrates preferential binding to insulin glargine (Lantus®), a widely-used basal insulin therapeutic. The antiserum is suitable for use in ELISAs/RIAs, as an immunoaffinity capture reagent in LC-MS/MS assays and for preparation of serum QCs for use in assays to detect and characterize ADA to glargine. The immunogen consisted of pharma-grade insulin glargine. Following immunization and boosting, the guinea pig antiserum was purified by a multi-stepped process which culminated in affinity-column chromatography to yield the purified antiserum. This resulting antiserum displays preferential binding for insulin glargine with only native insulin having more than 50% cross-reactivity. Suggested starting dilutions are: ELISA: 1/1,000 , RIA: 1/5,000, and immunoaffinity capture: 1/500
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
